Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters











Language
Publication year range
1.
The Korean Journal of Pain ; : 258-266, 2020.
Article | WPRIM (Western Pacific) | ID: wpr-835227

ABSTRACT

Background@#The genicular nerve block (GNB) is demonstrated from several reports to alleviate pain and improve knee functionality in patients with chronic knee osteoarthritis (OA). Ultrasound (US)-guided GNB has been the most used imaging method. This study aimed to compare the effectiveness of US-guided versus blind GNB in the treatment of knee OA. @*Methods@#This prospective, randomized clinical trial included patients with knee OA based on American College of Rheumatology diagnostic criteria. The patients were evaluated for clinical and dynamometer parameters at the baseline, 4 weeks after treatment, and 12 weeks after treatment. The patients underwent blind injection or US-guided injection. @*Results@#When compared with the baseline, both groups showed significant improvement in pain, physical function, and quality of life parameters. Significant differences were observed between the groups for clinical parameters (30-second chair stand test, 6-minute walk test) in favor of the US-guided group. On the other hand, blind injection was more significantly effective on some parameters of the Nottingham Health Profile. There wasn’t any significant improvement in isokinetic muscle strength for either group. @*Conclusions@#This study demonstrated that both US-guided and blind GNB, in the treatment of knee OA, were effective in reducing symptoms and improving physical function. GNB wasn’t an effective treatment for isokinetic muscle function. USguided injections may yield more effective clinical results than blind injections.

2.
Rheumatol Int ; 32(1): 241-4, 2012 Jan.
Article in English | MEDLINE | ID: mdl-20020139

ABSTRACT

Tumor necrosis factor-alpha (TNF-α) antagonists are employed increasingly during recent years in patients with active rheumatoid arthritis who do not respond to disease-modifying anti-rheumatic drugs. Contraindications such as infections, auto-antibody formation and hypersensitive reactions can be observed during the treatment with TNF-α antagonist drugs. Our case was a 52-year-old woman, followed by several centers for a period of 21 years with a seropositive, erosive and nodular RA diagnosis. Anti TNF-α treatment was commenced due to the failure to control the disease. During the treatment, a serious cellulite developed, which required hospitalization and surgical debridement as well as intravenous antibiotics treatment. Through the present case, we aimed to draw attention to the skin infection during the use of etanercept in a patient with RA.


Subject(s)
Arthritis, Rheumatoid/drug therapy , Cellulitis/chemically induced , Cellulitis/diagnosis , Immunoglobulin G/adverse effects , Immunoglobulin G/therapeutic use , Receptors, Tumor Necrosis Factor/therapeutic use , Anti-Bacterial Agents/therapeutic use , Antirheumatic Agents/adverse effects , Antirheumatic Agents/therapeutic use , Cellulitis/therapy , Debridement , Etanercept , Female , Humans , Middle Aged , Risk Factors , Treatment Outcome , Tumor Necrosis Factor-alpha/antagonists & inhibitors
SELECTION OF CITATIONS
SEARCH DETAIL